Tumor-derived VEGF, when combined with tumor-associated macrophages, can induce high expression of PD-1 and CTLA-4 on the surface of CD8+ T cells, leading to resistance to PD-1 and PD-L1 therapy (57). Here, CTLA4 is linked to neoplasm.